BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 ( NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the 'Company'), a developer and provider of innovative treatment programs for substance abuse and related disorders and USWM LLC, a specialty pharmaceutical company dedicated to addressing unmet medical needs, today announced that the Company's subsidiary BioCorRx Pharmaceuticals Inc., entered into a definitive agreement to acquire LUCEMYRA (lofexidine), a U.S. Food and Drug Administration (FDA) approved prescription medication for opioid withdrawal from USWM, LLC.
LUCEMYRA is the first and only non-opioid medication approved by the FDA to mitigate opioid withdrawal symptoms, providing critical relief for patients undergoing opioid detoxification. BioCorRx Pharmaceuticals Inc. projects LUCEMYRA to continue generating meaningful sales, positioning it as a key asset in BioCorRx Pharmaceutical Inc.'s expanding product line and represents its first FDA approved commercialized product.
Under the general terms of the agreement, USWM, LLC will retain a portion of future sales up to a capped amount in lieu of a direct cash payment at closing, BioCorRx Pharmaceuticals will pay a low single digit royalty to USWM, LLC, and USWM, LLC will receive shares of common stock and warrants from BioCorRx Inc.
Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented: 'This acquisition represents a significant milestone as we expand our addiction treatment offerings. LUCEMYRA provides a critical solution for patients experiencing opioid withdrawal, and we are excited to integrate it into our portfolio. We believe this strategic move will drive revenue growth and reinforce our commitment to combating the opioid crisis. Acquiring LUCEMYRA aligns with our mission to deliver innovative, non-opioid treatment solutions. By leveraging our expertise in behavioral health and our strong network of treatment centers, we aim to expand LUCEMYRA's market presence and improve access to opioid withdrawal treatment for those who need it most. Additionally, we believe that this acquisition will generate positive cash flow as we further develop our product pipeline and take the necessary steps to bring BICX104 to regulatory/FDA approval.'
P. Breckinridge Jones, Sr., CEO of USWM LLC, stated, 'We are proud of the impact LUCEMYRA has had in helping patients manage opioid withdrawal symptoms. Finding the right partner to continue its legacy was important to us, and BioCorRx's deep commitment to addiction treatment makes them an ideal fit. We look forward to working together through this transition and seeing the continued success of LUCEMYRA under BioCorRx's leadership.'
About BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx(R) Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx(R). The Company also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
About USWM LLC
USWM LLC is a privately held specialty pharmaceutical company that develops, licenses, and markets unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. More information on USWM LLC can be found at www.usworldmeds.com.
About LUCEMYRA (lofexidine)
LUCEMYRA (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal. It is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. In clinical trials, LUCEMYRA reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal. LUCEMYRA is administered A orally for up to 14 days, with dosing guided by symptoms. LUCEMYRA should be discontinued with gradual dose reduction over two to four days. The most common adverse reactions are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth.
About Opioid Withdrawal
Opioids lower norepinephrine, a brain chemical that supports vital functions like respiration and consciousness. With continued opioid use, the brain establishes a new equilibrium by increasing compensatory norepinephrine production in order to maintain normal functioning. When opioids are removed, or the dose is significantly reduced, the brain's increased norepinephrine levels are no longer offset by the presence of the opioids. This results in a norepinephrine surge that produces the acute symptoms of withdrawal.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'estimate,' 'become,' 'plan,' 'will,' and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Important Safety Information
What is LUCEMYRA?
LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder.
Important Safety Information
LUCEMYRA can cause serious side effects, including low blood pressure, slow heart rate, and fainting. Watch for symptoms of low blood pressure or heart rate, including dizziness, lightheadedness, or feeling faint at rest or when quickly standing up; if you experience these symptoms, call your healthcare provider right away and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. Avoid becoming dehydrated or overheated and be careful not to stand up too suddenly from lying or sitting, as these may increase your risk of low blood pressure and fainting. When your treatment is complete, you will need to stop taking LUCEMYRA gradually, or your blood pressure could increase. After a period of not using opioid drugs, you can become more sensitive to the effects of opioids if you start using them again. This may increase your risk of overdose and death. Before taking LUCEMYRA, tell your healthcare provider about all your medical conditions, including if you have low blood pressure, slow heart rate, any heart problems including history of heart attack or a condition called long QT syndrome, liver or kidney problems, or if you drink alcohol. Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding; it is not known if LUCEMYRA can harm your unborn baby or whether LUCEMYRA passes into your breast milk. Especially tell your healthcare provider if you take benzodiazepines, barbiturates, tranquilizers, or sleeping pills, as taking these with LUCEMYRA can cause serious side effects. The most common side effects of LUCEMYRA include low blood pressure or symptoms of low blood pressure such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here to see full Prescribing Information.
BioCorRx Inc.
[email protected]
714-462-4880
714-462-4880
Investor Relations:
Crescendo Communications, LLC
212- 671-1020 x304
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Regarding convocation of extraordinary general meeting of shareholders of public limited liability company 'Novaturas'
On 1 July 2025, the ordinary general meeting of shareholders (the Meeting) of Public limited liability company 'Novaturas', code 135567698, registered at A. Mickevičiaus str. 27, Kaunas, the Republic of Lithuania (the Company), is being convened upon the initiative and decision of the Board of the Company. The place of the Meeting (address): J. Jasinskio st. 16 C, Vilnius, Lithuania, Conference Centre, hall B. Start of the Meeting: the Meeting starts at 10:00 a.m. (registration of shareholders starts at 9:00 a.m.). The Meeting's accounting day – 24 June 2025. Only persons who are shareholders of the Company at the end of accounting day of the Meeting or persons authorized by them, or persons with whom shareholders concluded the agreements on the transfer of voting rights, shall have the right to attend and vote at the Meeting. The total number of shares of the Company, each with a nominal value of 0.03 euros, is 7,807,000. The number of shares granting voting rights at the Meeting is 7,751,003 (55,997 of its own shares have been acquired by the Company). ISIN code of the Company's shares – LT0000131872. Agenda of the Meeting: Consolidated Annual Report of the year 2024 of the Company; Independent auditor's report on the Company's set of audited annual financial statements and a set of the consolidated financial statements of the year 2024; Approval of the Company's set of audited annual financial statements and a set of the consolidated financial statements of the year 2024; Acceptance of the Company's remuneration report. Decision regarding distribution of profit (loss); Election of members of the Company's Board; Determination of remuneration for Board members, approval of the essential terms of contracts with Board members regarding their activities on the Board; Selection of the Company's audit firm to audit the set of annual financial statements for 2025-2026, determination of the terms of payment for audit services; Additional remuneration for members of the Company's Board; Establishment of additional payment terms for the audit services of the Company's audit firm UAB Ernst & Young Baltic for the audit of the set of annual financial statements for 2024. Draft decisions Draft decisions on issues of the agenda of the Meeting and other documents are attached to this report, as well as indicated in the Company's website at on the menu item 'For investors'. The shareholders can also familiarize themselves with this information by arriving at public limited liability company 'Novaturas' Vilnius filiale, address at J. Jasinskio str. 16C, Vilnius. Proposals for drafts decisions Each shareholder holding shares that grant at least 1/20 of all votes at any time before the Meeting or during the Meeting shall have the right to propose draft resolutions on the issues already included or to be included in the agenda of the Meeting. The proposed draft decisions must be presented to the Company in writing via registered mail or by providing them against signature at the registered office address of the Company indicated in the notice. The draft decisions verified by qualified e-signature are sent to email shareholder@ Supplementation of agenda The shareholders holding shares that grant at least 1/20 of all votes shall have the right to propose to supplement the agenda. Draft decisions on the proposed agenda items must be submitted together with the proposal or, if the decisions do not need to be adopted, explanations on each proposed item of agenda of the Meeting must be submitted. Proposal to supplement the agenda must be presented to the Company via registered mail or by providing it against signature at the address of the registered office of the Company indicated in the notice or via e-mail shareholder@ The agenda will be supplemented if the proposal is received not later than 14 days before the Meeting. Questions related to agenda items The shareholders shall have the right to present to the Company in advance in writing questions related to the agenda of the Meeting, by providing the shareholder's personal identification number and consent to process personal data – personal identification number in the letter which should be sent to the Company via registered mail or delivered against signature. The Company undertakes to respond if the questions are received not later than 3 business days prior to the Meeting. Responses of a general character shall be posted on the Company's website on the menu item 'For investors'. Participation and voting Shareholder or a person authorised by him/her/it shall have a right to vote in writing in advance by filling in the general voting ballot. Upon shareholder's request, the Company, not later than 10 days before the Meeting, shall send the general ballot paper by registered mail free of charge. The general voting ballot is also provided on the Company's website at on the menu item 'For investors'. The filled-in general voting ballot and the document confirming the voting right (if any) must be submitted to the Company via registered mail or provided against signature at the address of the registered office of the Company indicated in the notice and received by the Company not later than at 16:00 p.m. of the last business day prior to the Meeting. The filled-in and verified by qualified e-signature general voting ballot is send to e-mail shareholder@ The Company is not providing the possibility to attend and vote at the Meeting through electronic means of communication. Authorisations A person participating in the Meeting and having the right to vote must present a document certifying his/her identity. A person who is not a shareholder must, in addition to this document, submit a document confirming the right to vote at the general meeting of shareholders. Each shareholder shall have a right in the manner established by the laws to authorise other (natural or legal) person to attend and vote at the Meeting on his/her/its behalf. The authorized person must provide a power of attorney certified in the manner established by laws. A power of attorney issued in a foreign state must be translated into Lithuanian and legalised in the manner established by laws. Shareholder shall also have the right to authorize through electronic communication channels another person (natural or legal) to participate and vote in the repeated Meeting on shareholder's behalf. Such authorization may not be approved by the notary public. The power of attorney issued through electronic communication channels must be confirmed by the shareholder with a safe electronic signature developed by safe signature equipment and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder must inform the Company on the power of attorney issued through electronic communication channels via e-mail shareholder@ not later than until 16.00 p.m. of the last business day before the Meeting. The power of attorney and notification must be in writing. The power of attorney and notification to the Company must be signed with the electronic signature. The Company does not establish a special form of power of attorney. Attached: Meeting agenda and draft decisions. General voting ballot. AB Novaturas financial statements for 2024. Board's activity report for 2024. Board's activity plan for 2025. Audit and Risk Committee's activity report for 2024. Audit and Risk Committee's activity plan for 2025. Essential terms of the agreement for the activities of the Board member. Contacts: Darius UndzenasCFOJ. Jasinskio str. 16C, Vilnius, LithuaniaTel. +370 678 05749Tel. +370 614 44228 (Head of Legal)E-mail: shareholder@ Attachments 1 2025 GSM Agenda and drafts of decisions_EN 2 2025 Voting ballot Novaturas ENG 3.1 abnovaturas-2024-12-31-en 3.2 Novaturas AB - Opinion 24(IFRS, SA, Conso, ESEF) EN esigned 20250609 4 APPROVED_Board Report_2024 5 APPROVED_Board activity plan_2025 6 Approved_Audit and Risk Committee report_2024 7 APPROVED_Audit and Risk Committee plan_2025 8 Essential conditions with Board Members_LT-ENGError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Recall issued for potential significant risk with use of Zicam, Orajel swabs. What to know
A "potential microbial contamination" has lead to the recall of several cold nasal swabs and baby teething swabs, according to an announcement from the U.S. Food and Drug Administration June 9. All lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs have been recalled due to the potential contamination. The swabs can "potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections." Here's what you should know. Church & Dwight Co. is recalling all lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination identified as fungi in cotton swab components, according to a June 9 news release. The recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by the recall, the news released from the FDA said. As of June 9, "no serious adverse events" associated with the affected product have been reported, the FDA said. Recalled Zicam and Orajel swabs included in the recall are: Zicam Cold Remedy Nasal Swabs, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel Baby Teething Swabs, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. "Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. "The risk is highest — potentially severe or life-threatening — among children and individuals with compromised immune systems or other underlying medical conditions." The recalled products were distributed nationwide in the United States and in Puerto Rico. Consumers who have purchased any of the recalled products should stop using the product immediately, the FDA said. Go to or call the Consumer Relations team at 800-981-4710 for a full refund. This article originally appeared on Treasure Coast Newspapers: Zicam recall: cold nasal swabs. Also Orajel baby teething swabs
Yahoo
an hour ago
- Yahoo
Magma Silver Announces Marketing Agreement
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Magma Silver Corp. (TSXV: MGMA) (FSE: BC21) (WKN: A411DV) (the "Company") is pleased to announce it has entered into a marketing agreement (the "Agreement") with Epstein Research (Peter Epstein) ("Epstein") pursuant to which Epstein will provide investor relation services to the Company in consideration for an aggregate of US$15,000 at a rate of US$,2,500 per month. The Company has the right to renew the Agreement for an additional 6 months, subject to the approval of the TSXV. The Agreement is for an initial term of 6 months commencing on June 9, 2025, and, in accordance with its terms, Epstein will work with the Company on posting on social media, producing monthly articles and commentary designed to develop a positive and productive profile for the Company within the marketplace. The Agreement has been conditionally approved by the TSX Venture Exchange. Epstein operates the website Epstein does not own any securities of the Company or any right to acquire securities of the Company. Epstein is an arm's length party to the Company. Mr. Epstein has a background in company & financial analysis, including having earned an MBA in Financial Analysis at NYU's Stern School of Business. Epstein has over 20 years in buy-side analyst roles. About Magma Silver Corp. Magma Silver Corp. is a natural resource company with a focus on the acquisition, exploration, development, and operation of precious metal mining exploration projects. The Company's primary focus is on exploring and developing the advanced Niñobamba silver gold project in the mining supportive country of Peru. For further information, please contact Magma Silver Corp.:Jason Baker, Chief Financial OfficerPhone: +1-604-252-2672Email: info@ Website: Reader Advisory This news release may contain forward-looking information within the meaning of applicable securities laws. All information and statements other than statements of current or historical facts contained in this news release are forward-looking information. Forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Magma Silver Corp.'s periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "should," and similar expressions, are forward-looking statements. The information provided in this document is necessarily summarized and may not contain all available material information. Forward-looking statements include those in relation to (i) the Agreement and the performance thereof, (ii) the expected benefits to the Company from the Agreement and the scope of services to be provided by Epstein. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can't make any assurances that its expectations will be achieved. Such assumptions may prove incorrect. Although the Company has attempted to identify important factors that could cause actual results, performance, or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance, or achievements not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances, or results will materialize. As a result of these risks and uncertainties, no assurance can be given that any events anticipated by the forward-looking information in this news release will transpire or occur, or, if any of them do so, what benefits that the Company will derive therefrom. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company disclaims any intention or obligation to update or revise such information, except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
